Europe Prostate Cancer Diagnostics Market Set for Strong Growth Through 2033

The Europe Prostate Cancer Diagnostics Market is on a solid growth trajectory, projected to rise from US$ 53.25 billion in 2024 to US$ 97.73 billion by 2033, registering a CAGR of 6.98% over the forecast period 2025–2033, according to Renub Research. The rapid growth is driven by the increasing prevalence of prostate cancer, improvements in diagnostic imaging and molecular testing, large-scale screening initiatives, and supportive healthcare policies across European nations.

Prostate cancer remains one of the most diagnosed cancers among European men, especially those above 50 years of age. As a result, early detection has become a key public health priority in the region, prompting strong investments in diagnostic technologies—from PSA testing and MRI to cutting-edge genomic profiling.

Download Sample Report

Understanding Europe’s Prostate Cancer Diagnostics Landscape

Prostate cancer diagnostics refers to the set of tests and procedures used to detect cancer in the prostate gland. The most common modalities include:

Prostate-Specific Antigen (PSA) Blood Tests

Digital Rectal Examination (DRE)

MRI and Multiparametric MRI (mpMRI)

Ultrasound-Guided Biopsies

Genomic and Molecular Tests

These tools have become vital due to Europe’s aging male population, rising patient awareness, and evolving clinical guidelines that recommend early and precise diagnostic measures.

Countries such as Germany, the United Kingdom, France, Italy, and the Netherlands have sophisticated diagnostic infrastructures that include MRI fusion biopsy systems, molecular labs, and streamlined referral pathways for high-risk men.

Moreover, advancements like AI-integrated imaging, liquid biopsy, and next-generation sequencing (NGS) are transforming prostate cancer diagnosis from a one-size-fits-all process to personalized diagnostics.

Key Market Drivers

1. Rising Prevalence Among the Aging Population

Europe has one of the world’s oldest demographics. Prostate cancer diagnosis is significantly higher among men aged above 50—and Europe’s senior population continues to expand.

According to European Union health statistics from October 2024,

31% of men and 25% of women are likely to be diagnosed with cancer before age 75.

14% of men and 9% of women may die from cancer before 75.

As life expectancy rises, more men fall into at-risk categories, increasing the demand for early prostate cancer screening and diagnostic tests. Regular check-ups, widespread cancer literacy, and government-funded screening programs are pushing more individuals toward early evaluation.

2. Breakthroughs in Diagnostic Technology

Europe is a global frontrunner in adopting emerging prostate cancer diagnostic technologies. High-precision diagnostic tools such as:

Multiparametric MRI (mpMRI)

MRI-targeted biopsy techniques

AI-powered imaging software

Genomic and molecular assays

Liquid biopsies

Next-Generation Sequencing (NGS)

have greatly improved cancer detection accuracy.

MRI-targeted biopsies, for example, significantly reduce unnecessary invasive biopsies and help identify clinically meaningful cancers early.

In June 2023, Sysmex Europe introduced a rapid antimicrobial susceptibility testing system designed for UTI samples. While not directly a prostate cancer test, innovations like these reinforce Europe’s strong diagnostic ecosystem and signal wider adoption of advanced laboratory technologies.

European health institutions and startups are also pioneering AI-integrated prostate cancer screening, making imaging more consistent and less operator-dependent.

3. Strong Government Support and Public Health Initiatives

European governments play a substantial role in promoting prostate cancer screening through:

National awareness campaigns

Reimbursement support

Physician education programs

Research funding

Organized screening pilot programs

The European Association of Urology (EAU) continues to promote standardized PSA testing and early detection frameworks across EU nations.

In April 2023, All.Can and the EFPIA Oncology Platform (EOP) launched a partnership to promote evidence-based implementation of EU Cancer Screening Recommendations in Belgium, Italy, Spain, and Romania—demonstrating the EU’s strategic focus on early cancer detection.

This environment has created a robust ecosystem for diagnostic manufacturers, laboratories, and healthcare institutions, driving deeper market penetration and patient access.

Key Market Challenges

1. Differing Screening Policies Across Europe

Despite medical science confirming the benefits of early detection, prostate cancer screening recommendations are not uniform across Europe.

Some countries promote routine PSA testing, while others exercise caution due to the risk of overdiagnosis. Cultural attitudes toward preventive care also vary widely.

For example:

Scandinavian countries tend to be more conservative with PSA-based screening.

Germany and the UK encourage PSA testing for older men during routine check-ups.

Eastern European nations face lower public awareness but rising government efforts.

The lack of a standardized EU-wide screening standard contributes to uneven diagnostic adoption and missed early detection opportunities.

2. High Cost of Advanced Diagnostic Modalities

Leading-edge technologies such as genomic tests, mpMRI-guided biopsies, and liquid biopsies are significantly costlier than traditional PSA tests.

Challenges include:

Limited reimbursement in some countries

High capital investment for MRI and diagnostic infrastructure

Affordability issues in Eastern and rural Europe

Slow adoption in public hospitals

The absence of large-scale cost-effectiveness studies in some countries also causes clinicians to hesitate before adopting newer diagnostic tools.

Until these costs reduce or reimbursement expands, the market may experience uneven growth among economically diverse European regions.

Segmental Market Overview

Europe Prostate Cancer Diagnostics Market Overview

The market is poised for steady growth due to technological progress and public awareness initiatives. Diagnostic approaches span PSA tests, DRE, biopsies, MRI imaging, and genetic profiling.

Western Europe dominates due to better healthcare infrastructure and funding. Moreover, integrations between hospitals, diagnostic labs, and research institutions are enhancing early disease detection rates.

Europe Benign Prostatic Hyperplasia (BPH) Market

BPH (Benign Prostatic Hyperplasia) is not cancer, but its symptoms often overlap with prostate cancer. This overlap increases diagnostic volume across Europe.

Tools commonly used to differentiate BPH from cancer include:

PSA Tests

Transrectal Ultrasound

Urodynamic Testing

Growing BPH awareness, especially among elderly men, contributes indirectly to the rise in prostate cancer diagnostics demand.

Europe Initial Prostate Cancer Tests Market

Initial screening tests—PSA tests and DRE—form the first line of diagnosis.

PSA testing remains:

Affordable

Non-invasive

Widely accessible

Countries such as Germany, Italy, and the UK have incorporated PSA testing into routine medical check-ups for older men. As regular health screening becomes more common, the initial test segment will continue driving early detection.

Europe Prostate Cancer Diagnostics Hospitals Market

Hospitals remain the backbone of prostate cancer diagnostic services. They offer:

mpMRI systems

Full biopsy suites

Molecular pathology labs

Multidisciplinary urology–oncology teams

Both public and private hospitals are deploying AI-based biopsy robots and automated pathology tools to enhance accuracy and reduce waiting times.

Teaching hospitals also participate in clinical trials, accelerating the adoption of precision diagnostic techniques.

Europe Prostate Cancer Diagnostic Centers Market

Standalone diagnostic centers are rapidly expanding due to:

Faster appointment scheduling

Lower wait times

Specialist urologists

Access to mpMRI and genomic testing

These centers also collaborate with community screening campaigns, expanding access to rural and underserved populations. Their patient-centered approach has made them indispensable to the continent’s diagnostic infrastructure.

Country-Level Market Analysis

Germany

Germany leads the European prostate cancer diagnostics market. With universal health insurance, high diagnostic spending, and excellent medical infrastructure, Germany has widespread PSA testing uptake.

The country also pioneers:

mpMRI adoption

AI-enhanced radiology

Genomic and molecular profiling

Germany’s focus on precision medicine makes it a trendsetter in prostate cancer diagnostics.

United Kingdom

The UK continues to experience rapid growth in the prostate diagnostics industry, supported by the NHS, strong clinical research, and rising public awareness.

Although PSA testing is not part of a nationwide screening program, general practitioners widely recommend it for high-risk populations. The UK is also known for groundbreaking prostate cancer R&D and AI-imaging research.

Russia

Russia’s diagnostics market is growing but faces regional disparities. Cities like Moscow and St. Petersburg boast advanced diagnostic facilities, while rural areas struggle with access.

Government cancer programs are improving PSA testing awareness, but challenges remain in terms of funding and infrastructure. Nevertheless, ongoing reforms signal long-term improvement in diagnostic coverage.

Market Segmentation

By Type

Benign Prostatic Hyperplasia

Prostatic Adenocarcinoma

Small Cell Carcinoma

Others

By Test Type

Preliminary Tests

Confirmatory Tests

By End User

Hospitals

Diagnostic Centers

Research Institutes

Others

By Country

France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Russia, Poland, Greece, Norway, Romania, Portugal, Rest of Europe.

Key Companies Covered

F. Hoffmann-La Roche AG

Bayer AG

Thermo Fisher Scientific Inc.

Abbott Laboratories

Siemens Healthineers AG

Becton Dickinson and Company

Agilent Technologies Inc.

Hologic Inc.

Qiagen N.V.

OPKO Health Inc.

Each company profile includes:

Overview

Key Person

Recent Developments

SWOT Analysis

Revenue Analysis

Final Thoughts

Europe’s prostate cancer diagnostics market is entering a period of unprecedented growth and innovation. With the population aging rapidly and cancer awareness reaching new heights, early detection is becoming a healthcare priority rather than an option. Technological advances—from AI to molecular tests—are raising diagnostic precision and improving patient outcomes.

However, the path forward requires addressing critical challenges such as varying screening guidelines and the high cost of advanced diagnostics. As Europe continues harmonizing public health policies and investing in early detection, the region is poised to become a global benchmark for prostate cancer diagnostics over the next decade.